Study of LUCAR-20S in Patients With R/R NHL

Nanjing Medical University

Status and phase

Terminated

Phase 1

Conditions

Small Lymphocytic Lymphoma

Mantle Cell Lymphoma

Follicular Lymphoma

Diffuse Large B Cell Lymphoma

Treatments

Drug: LUCAR-20S CAR-T cells

Study type

Interventional

Funder types

Other

Identifiers

NCT04176913

BM2L201904 (Registry Identifier)

Details and patient eligibility

About

An open label, single arm Phase I study to evaluate the safety, tolerability, and pharmacokinetics of LUCAR-20S CAR-T cells in relapsed or refractory CD20+ diffuse large B-cell, follicular, mantle cell and small lymphocytic lymphoma.

Full description

This study is an open, dose escalation/dose regimen finding study to assess the safety and pharmacokinetics of donor-derived CD20-directed CAR-T cells administered with lymphodepletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD20 positive diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma or small lymphocytic lymphoma. The allo-CAR-T cells will be infused in single-dose.

Enrollment

7 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Signed informed consent form (ICF)
Age 18 Years to 75 Years
Pathological diagnosis of refractory/relapsed CD20+ non-Hodgkin's lymphoma (one of the following):
1. Diffuse large B-cell lymphoma (DLBCL)
2. Follicular lymphoma (FL)
3. Mantle cell lymphoma (MCL)
4. Small lymphocytic lymphoma (SLL)
Measurable disease as defined by 2014 Lugano criteria at Screening
Refractory/relapsed disease after standard-of- care treatment as following (Undergone at least 2 complete cycle of therapy for each line, unless PD been documented as the best response to the regimen) and not eligible or appropriate for HSCT (Auto/allo). Subject must have documented evidence of progressive disease on or within 12 months of their last regimen.
1. DLBCL: Refractory/relapsed after at least 1 prior line of therapy, must have been treated with anti-CD20 monoclonal antibody
2. FL: Refractory/relapsed after at least 2 prior lines of therapy, must have been treated with anti-CD20 monoclonal antibody
3. MCL: Refractory/relapsed after at least 2 prior lines of therapy
4. SLL: Refractory/relapsed after at least 2 prior lines of therapy
Laboratory criteria at Screening

① Blood routine: NE≥1.0×109/L；HGB≥8g/dL；PLT≥50×109/L

② Blood biochemical parameters:
1. Total bilirubin ≤ 1.5 times of the normal upper limit (ULN)
2. Aspartate and alanine aminotransferases (AST, ALT) ≤ 3 times ULN (in the presence of liver metastasis, ULN 5 times)
3. Estimated glomerular filtration rate (eGFR) > 60mL/min
Life expectancy > 12 weeks
Eastern Cooperative Oncology Group (ECOG) Performance Status grade of 0 or 1

Exclusion criteria

Any malignancy besides the NHL categories under study, exceptions include
1. Any other malignancy curatively treated and disease-free for at least 2 years prior to enrollment
2. History of non-melanoma skin cancer with sufficient treatment and currently no evidence of recurrence
Prior treatment with an allogeneic stem cell transplant
Prior treatment with genetic therapy
Prior treatment with chimeric antigen receptor T (cells) CAR-T therapy directed at CD20 target
Those who are positive for any index of hepatitis B surface antigen (HBsAg), hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C antibody (HCV-Ab), hepatitis C virus ribonucleic acid (HCV RNA), and human immunodeficiency virus antibody (HIV-Ab)
Prior antitumor therapy with insufficient washout period
1. Targeted therapy, epigenetic therapy, experimental drug therapy or experimental invasive treatment with medical apparatus and instruments 14 days or five half-lives, whichever is shorter before lymphodepletion
2. Use of monoclonal antibodies 21 days prior to lymphodepletion
3. Chemotherapy within 14 days prior to lymphodepletion
4. Radiotherapy within 14 days prior to lymphodepletion
5. Participated in other clinical trials within 30 days prior to lymphodepletion
With central nervous system involvement
Women in pregnancy or lactation
Being fertile and unable to use effective conception during treatment and 100 days after CAR-T infusion
Active autoimmune disease or history of autoimmune disease within 3 years
With obvious hemorrhagic tendency such as gastrointestinal hemorrhage, coagulation disorders and hypersplenism
The following cardiac conditions
1. New York Heart Association (NYHA) stage III or IV congestive heart failure
2. Left ventricular ejection fraction (LVEF) less than (<)45%
3. Uncontrolled cardiac arrhythmia post-medication
4. With a history of myocardial infraction or unstable angina pectoris within the past 6 months
5. Constrictive pericarditis
6. Cardiomyopathy
Pulse oximetry of <96% on room air
Active or uncontrolled infection requiring parenteral antibiotics, or any evidence of severe active viral/bacterial infection or uncontrolled systemic fungal infection
Uncontrolled diabetes mellitus, defined as fast serum glucose > 1.5 times ULN
Concurrent use of corticosteroids or other immunosuppressant medications for chronic disease
Concurrent use of hematopoietic growth factor
Stroke or seizure within 6 months of signing ICF
Have received any live, attenuated vaccine within 4 weeks prior to lymphodepletion
Have underwent major surgical operation within 2 weeks prior to lymphodepletion, or anticipate to undergo a major surgical operation during the study process or within 2 weeks posterior to study treatment(with the exception of anticipated local anesthesia surgery)
Known life threatening allergies, hypersensitivity, or intolerance to LUCAR-20S CAR-T cells or its excipients, including dimethyl sulfoxide (DMSO)
Presence of any condition that, in the opinion of the investigator, would prohibit the patient from undergoing treatment under this protocol